⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17074780 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL519119 | 0.97 | — | — | |
| SCHEMBL1579734 | 0.81 | — | — | |
| Nitric Acid SCHEMBL29142706 | 0.81 | POLB (0.38) | — | |
| SCHEMBL19480310 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL18726122 | 0.79 | TDP1 (0.52) | — | |
| SCHEMBL24553869 | 0.79 | PRMT3 (0.35) | — | |
| SCHEMBL15426781 | 0.78 | — | — | |
| SCHEMBL19981041 | 0.73 | — | — | |
| SCHEMBL22416393 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3789395-B1 | PEGYLATION OF FGF21 | BRISTOL MYERS SQUIBB CO (US) | 2025-08-27 | — | — | EP | claimed |
| CN-115819494-A | Additive system for protein pegylation | 百时美施贵宝公司 | 2023-03-21 | — | — | CN | claimed |
| CN-108350025-B | Additive system for protein pegylation | 百时美施贵宝公司 | 2023-02-21 | — | — | CN | claimed |
| US-20220160883-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | claimed |
| EP-3789395-A1 | PEGYLATION OF FGF21 | Bristol-Myers Squibb Company (US) | 2021-03-10 | — | — | EP | claimed |
| EP-3546066-B1 | AMPHOTERIC DISSOCIATION ION EXCHANGE MEDIUM, ITS USE, AND SEPARATION CAPACITY CALIBRATION METHOD | CHONGQING BOLANYING BLY BIOTECHNOLOGY CO LTD CHINA (CN) | 2021-01-20 | — | — | EP | claimed |
| US-20200276319-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | claimed |
| EP-3380487-B1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL MYERS SQUIBB CO (US) | 2020-09-02 | — | — | EP | claimed |
| US-20190351065-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-11-21 | — | — | US | claimed |
| US-20190291095-A1 | AMPHOTERIC DISSOCIATION ION EXCHANGE MEDIUM AND USES THEREOF AND METHOD FOR CALIBRATING SEPARATION CAPACITY THEREOF | CHONGQING BOLANYING BLY BIOTECHNOLOGY CO LTD (CN) | 2019-09-26 | — | — | US | claimed |
| CN-108350025-A | additive system for protein PEGylation | 百时美施贵宝公司 | 2018-07-31 | — | — | CN | claimed |
| EP-4689608-A2 | METHODS AND SYSTEMS FOR LABEL-FREE DE NOVO SEQUENCING | Pumpkinseed Technologies, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12498379-B2 | Solid-phase N-terminal peptide capture and release | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-12-16 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250283145-A1 | METHODS FOR BASE-LEVEL DETECTION OF METHYLATION IN NUCLEIC ACIDS | Roche Sequencing Solutions, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-4145432-A | 6-ACYLORYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND A METHOD OF EFFECTING VASODILATION THEREWITH | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-03-20 | — | — | US | disclosed |
| US-4080503-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS, ANTIARRHYTHMICS | BOEHRINGER INGELHEIM GMBH (DT) | 1978-03-21 | — | — | US | disclosed |
| US-4026899-A | PARASITICIDES | PARKE, DAVIS & COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
| US-3963740-A | PARASITICIDE | PARKE, DAVIS & COMPANY (US) | 1976-06-15 | — | — | US | disclosed |
| US-3957762-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-05-18 | — | — | US | disclosed |